Table 2.
Breast Cancer-Specific Survival | Recurrence | |||||||
---|---|---|---|---|---|---|---|---|
All women, adjusted | Deaths1 | HR2,3 | 95%CI | Recurrences | HR | 95%CI | ||
18.5-<25-kg/m2 | 119 | Reference | 147 | Reference | ||||
25-<30-kg/m2 | 90 | 0.94 | 0.71 | 1.24 | 111 | 0.94 | 0.69 | 1.29 |
30-<35-kg/m2 | 57 | 0.98 | 0.71 | 1.36 | 66 | 0.98 | 0.67 | 1.43 |
≥35-kg/m2 | 46 | 1.06 | 0.74 | 1.52 | 54 | 1.02 | 0.67 | 1.54 |
Per 5-unit BMI | 312 | 1.05 | 0.95 | 1.15 | 378 | 1.03 | 0.92 | 1.14 |
Luminal A | ||||||||
18.5-<25-kg/m2 | 43 | Reference | 52 | Reference | ||||
25-<30-kg/m2 | 31 | 1.36 | 0.84 | 2.19 | 39 | 1.43 | 0.78 | 2.62 |
30-<35-kg/m2 | 17 | 1.29 | 0.72 | 2.33 | 18 | 1.05 | 0.50 | 2.18 |
≥35-kg/m2 | 19 | 2.24 | 1.22 | 4.11 | 21 | 2.17 | 0.92 | 5.11 |
Per 5-unit BMI | 110 | 1.31 | 1.11 | 1.54 | 130 | 1.24 | 1.00 | 1.54 |
Luminal B | ||||||||
18.5-<25-kg/m2 | 32 | Reference | 39 | Reference | ||||
25-<30-kg/m2 | 26 | 0.62 | 0.36 | 1.06 | 33 | 0.67 | 0.27 | 1.71 |
30-<35-kg/m2 | 25 | 1.39 | 0.80 | 2.41 | 30 | 1.69 | 0.62 | 4.64 |
≥35-kg/m2 | 11 | 0.61 | 0.29 | 1.29 | 13 | 0.58 | 0.15 | 2.21 |
Per 5-unit BMI | 94 | 0.99 | 0.83 | 1.18 | 115 | 0.98 | 0.71 | 1.35 |
Basal-Like | ||||||||
18.5-<25-kg/m2 | 17 | Reference | 18 | Reference | ||||
25-<30-kg/m2 | 18 | 1.23 | 0.63 | 2.43 | 20 | 1.18 | 0.55 | 2.57 |
30-<35-kg/m2 | 8 | 0.52 | 0.22 | 1.26 | 10 | 0.72 | 0.14 | 3.68 |
≥35-kg/m2 | 9 | 0.67 | 0.28 | 1.59 | 11 | 0.75 | 0.25 | 2.25 |
Per 5-unit BMI | 52 | 0.90 | 0.73 | 1.11 | 59 | 0.93 | 0.74 | 1.17 |
Her2-Overexpressing | ||||||||
18.5-<25-kg/m2 | 27 | Reference | 38 | Reference | ||||
25-<30-kg/m2 | 15 | 0.78 | 0.40 | 1.51 | 19 | 0.66 | 0.17 | 2.50 |
30-<35-kg/m2 | 7 | 0.69 | 0.28 | 1.71 | 8 | 0.54 | 0.06 | 5.16 |
≥35-kg/m2 | 7 | 0.89 | 0.37 | 2.15 | 9 | 0.79 | 0.21 | 2.99 |
Per 5-unit BMI | 56 | 0.92 | 0.71 | 1.20 | 74 | 0.87 | 0.53 | 1.41 |
Number of events is unweighted.
Hazard ratios and confidence intervals are weighted to account for stratified case-cohort study design with strata defined as IHC clinical subtype.
Adjusted for for age, menopausal status, race/ethnicity, study, stage and receipt of any chemotherapy.